Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GlaxoSmithKline (GSK) Share Price & Analysis
435 Followers
GSK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,264.04p - 1,821.00p
Previous Close1,810p
Volume588.01K
Average Volume (3M)7.91M
Market Cap
£73.84B
Enterprise Value86.10B
Total Cash (Recent Filing)£5.18B
Total Debt (Recent Filing)£18.02B
Price to Earnings (P/E)16.4
Beta0.45
Next Earnings
Jul 31, 2024EPS Estimate
£0.38Next Dividend Ex-Date
May 16, 2024Dividend Yield3.2%
Share Statistics
EPS (TTM)1.10
Shares Outstanding4,117,033,438
10 Day Avg. Volume11,123,383
30 Day Avg. Volume7,908,148
Standard Deviation0.05
R-Squared0.29
Alpha0.00638
Financial Highlights & Ratios
Price to Book (P/B)-9.05
Price to Sales (P/S)242.10
Price to Cash Flow (P/CF)6.90
P/FCF Ratio8.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,939.10pPrice Target Upside6.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
GlaxoSmithKline News
PremiumCompany Announcements
GSK Executives Invest in Company’s Future
PremiumCompany Announcements
GSK Shareholders Display Strong Confidence at AGM
PremiumCompany Announcements
GSK Announces Board Committee Appointments
PremiumCompany Announcements
GSK Executive Sells Shares on London ExchangeBulls Say, Bears Say
Bulls Say
Earnings GrowthAnalyst recommends upgrading GSK to BUY from NEUTRAL following key revenue updates and increased confidence in margin benefits, indicating attractive upside potential in the stock.
Financial PerformanceCompleted a strong set of quarterly numbers, significantly exceeding consensus estimates.
Product PerformanceVaccines division outperformed expectations, particularly Shingrix in China.
Bears Say
Litigation RisksZantac litigation presents a non-zero risk of some or all of the 73K cases progressing to trial.
Pipeline ChallengesPipeline, although improving, still too early to have confidence in its ability to offset the dolutegravir cliff.
Product PerformanceVaccines sales are below consensus with Arexvy underperforming expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.29% Insiders
10.84% Mutual Funds
10.28% Other Institutional Investors
77.59% Public Companies and Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1264.04p and its highest was 1821.00p in the past 12 months.
What is GlaxoSmithKline’s market cap?
Currently, no data Available
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Jul 31, 2024 which is in 77 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on May 01, 2024. The company reported 0.431p earnings per share for the quarter, beating the consensus estimate of 0.367p by 0.064p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15p which represents an annual dividend yield of 3.2%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is £0.38.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,144,924,000 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.431p in its last earnings report, beating expectations of 0.367p. Following the earnings report the stock price went up 1.913%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
1,939.10p (6.98% Upside)
1,939.10p (6.98% Upside)
Insider Transactions
Sold Shares
Worth £5.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.11%
12-Months-Change
Fundamentals
Return on Equity
34.95%
Trailing 12-Months
Asset Growth
-0.14%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Month Forecast
Average Price Target
1,939.10p
▲(6.98% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
26/33 ratings generated profit
1 Year Average Return
+12.06%
reiterated a buy rating 14 days ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 78.79% of your transactions generating a profit, with an average return of +12.06% per trade.
---